Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。

サイズ 価格 在庫  
JPY 22318.14 あり
JPY 12958.92 あり
JPY 24477.96 あり
JPY 46076.16 あり
JPY 82073.16 あり

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MojySpVv[3Srb36gRZN{[Xl? M1;velAvPcLizszN MlvsNlQhcA>? Mnrye4F1\XJ? M1f6SI1w\HWuYYTld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIF3BS2UuSSCvZX3i[ZJ{ NIHSUnYzPTF{M{C4Ni=>
Eca109 NXe0SXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vEXlAvPS9{LkWvOUDPxE1? NWS3fpRxOjRxNEivO|IhcA>? M3TYSZdifGW{ NFLUeZhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MXKyOVEzOzB6Mh?=
Eca109 NHzFOmxHfW6ldHnvckBCe3OjeR?= NYjINmRWOC53wrFOwG0> NVHWOFlsPi9zMj:yOEBp NYrTcFV{f2G2ZYK= NVz6e3Z{cW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> M3f4OlI2OTJ|MEiy
Eca109 MVPGeY5kfGmxbjDBd5NigQ>? M3T5[|AvPcLizszN NEHKNpEzPCCq NX\vRnh7f2G2ZYK= MXPpcohq[mm2czDj[YxtKGmwdnHzbY9v NVPBe404OjVzMkOwPFI>
Eca109 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:2SZBiOC53wrFOwG0> M1Po[VI1KGh? MWT3ZZRmeg>? Mlz3bY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> M4nOSFI2OTJ|MEiy
Eca109 NFnrSmlHfW6ldHnvckBCe3OjeR?= NWruW4x3OC53L{Gg{txO NWXIUJRmOjRiaB?= NF;QNnR4[XSnch?= NHjNd2Nl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{ NVL3VYJEOjVzMkOwPFI>
SW1116  MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\jbYM2OC53L{GvNk82KM7:TR?= MWe0PEBp NHjOW45FVVOR MVzlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u M{PDWVI1QDd2Mki2
LOVO MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;pfmtNOC53L{GvNk82KM7:TR?= MVW0PEBp NFewVYVFVVOR MlPm[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MYGyOFg4PDJ6Nh?=
SW1116  M1HKXmZ2dmO2aX;uJGF{e2G7 NXfYelA1OTBizszN MlHaOFghcA>? MkXiSG1UVw>? NYPZ[ZJZcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk NGX3SJgzPDh5NEK4Oi=>
LOVO NF6weo1HfW6ldHnvckBCe3OjeR?= M2TVWlExKM7:TR?= NEG5NXA1QCCq MnP1SG1UVw>? Mln1bY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MXWyOFg4PDJ6Nh?=
SW1116  M4\W[2Fxd3C2b4Ppd{BCe3OjeR?= MVexNEDPxE1? NVnl[YdRPDhiaB?= M4q5d2ROW09? MWTlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NX[2fGZSOjR6N{SyPFY>
LOVO NW\CO3JHSXCxcITvd4l{KEG|c3H5 M{THXlExKM7:TR?= NXjhVYRkPDhiaB?= MoXwSG1UVw>? NXr6PG1Q\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MoDRNlQ5PzR{OE[=
RPMI-8226 MkfDRZBweHSxc3nzJGF{e2G7 NWDuVXptOS9{IN88US=> M3nmSVQ5Nzd{L{m2JIg> MX3EUXNQ MlHBbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mln6NlQ5OzNzMEi=
OPM-2  NV22fmFCSXCxcITvd4l{KEG|c3H5 NF\ZeGoyNzJizszN NIPyOXU4Oi97Nj:xNlAhcA>? NHfjfJFFVVOR MlzxbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NX\Qd443OjR6M{OxNFg>
JJN3  MoXtRZBweHSxc3nzJGF{e2G7 NIfUUXIxNjVxMTFOwG0> MV2yOE81QCCq MYfEUXNQ NIW3VIpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnG4NlQ5OzNzMEi=
NCI-H929  M{jY[mFxd3C2b4Ppd{BCe3OjeR?= MWCxM|Ih|ryP MV[3Nk86Pi9zMkCgbC=> MkLTSG1UVw>? Moi4bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NH;qPZAzPDh|M{GwPC=>
RPMI-8226 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S0TVEwOiEQvF2= NIjneGIzPC92OD:3NkBp MofaSG1UVw>? M{KyRYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MUWyOFg{OzFyOB?=
OPM-2  NYPa[I9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nxOlEwOiEQvF2= NEHq[WkzPC92OD:3NkBp M3LRb2ROW09? MXXh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MnP2NlQ5OzNzMEi=
JJN3  M{nMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3OVJp1OC53L{Gg{txO MXSyOE81QC95MjDo NFjRc4NFVVOR MWrh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NG[5UokzPDh|M{GwPC=>
NCI-H929  NEfvdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkniNU8zKM7:TR?= MUCyOE81QC95MjDo NEizdVZFVVOR NUO1[nUx[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= Mo[4NlQ5OzNzMEi=
HeLa NYjuOXUxU2mwYYPlJGF{e2G7 NXfCZ|NIU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? NF3HSG4zPDd6MEC5PC=>
HeLa NEX6SGRMcW6jc3WgRZN{[Xl? MmfsT4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy NGXkXnQzPDd6MEC5PC=>
HeLa Mlr1T4lv[XOnIFHzd4F6 MknWT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> MYGyOFc5ODB7OB?=
HeLa NUXxR5UxU2mwYYPlJGF{e2G7 M{nafGtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> M3O2XlI1PzhyMEm4
NB4 NFv1cIRHfW6ldHnvckBCe3OjeR?= MX6yMlUwPS95LkWvNVAh|ryP NUX4NHh5OjRiaB?= M3[1TGROW09? MYXpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NVTPfZN4OjR2OES4O|A>
CD4+ CD25− T  NGXNNZFHfW6ldHnvckBCe3OjeR?= MUOxM|Uh|ryP NVntdmNiemWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w M13aRVI1PDd4M{[w
BV-173 NEHDZ2NCeG:ydH;zbZMhSXO|YYm= MXKwMlI2NzBwNT:wMlc2NzFizszN NUmydo5tPDhxN{KvPVYhcA>? MV|CpHBDWw>? NY[1UlBZcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MnjBNlQ1OjN4MUO=
ML-1 NIPZbnlCeG:ydH;zbZMhSXO|YYm= NEK3[oExNjJ3L{CuOU8xNjd3L{Gg{txO MXS0PE84Oi97NjDo MWVCpHBDWw>? NFXBOnNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> M37O[VI1PDJ|NkGz
HL-60 NVrpSVFnSXCxcITvd4l{KEG|c3H5 MYKwMlI2NzBwNT:wMlc2NzFizszN M1ywVVQ5Nzd{L{m2JIg> NIDnVGHDqFCEUx?= MX;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MkmyNlQ1OjN4MUO=
KG-1a NIn1Um9CeG:ydH;zbZMhSXO|YYm= M4HTcVAvOjVxMD61M|AvPzVxMTFOwG0> MkS2OFgwPzJxOU[gbC=> MnKyxsBRSlN? NVXhfHhWcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M2PmWFI1PDJ|NkGz
BV-173 NV3JUVZZTnWwY4Tpc44hSXO|YYm= NIjSdnozPTBxNUCwcm0> M1jwWVQ5KGh? NVHlbHNGyqCSQmO= MlTQbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MkLiNlQ1OjN4MUO=
CEM MmPQSpVv[3Srb36gRZN{[Xl? M4q5fVI2OC93MEDuUS=> NYG2fJF1PDhiaB?= MojJxsBRSlN? MkTsbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M2XE[lI1PDJ|NkGz
HL-60 NVX4b5JJTnWwY4Tpc44hSXO|YYm= MVqyOVAwPTBybl2= NH[1cHA1QCCq NIjsOm3DqFCEUx?= NHfpdGlqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= Ml;qNlQ1OjN4MUO=
ML-1 NF;GZ25HfW6ldHnvckBCe3OjeR?= NGq1U4UzPTBxNUCwcm0> MUC0PEBp NVTlbII1yqCSQmO= Mn3JbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NH;4[2QzPDR{M{[xNy=>
DLD-1 MmHoSpVv[3Srb36gRZN{[Xl? M{\1UVI2OC93MEDuUS=> NXLkU454PDhiaB?= MXhCpHBDWw>? MX7kc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NIXXVIUzPDR{M{[xNy=>
HCT-116 NYCwWVNsTnWwY4Tpc44hSXO|YYm= NFHiWpYzPTBxNUCwcm0> MmPGOFghcA>? M3\veOKhWEKV MVLkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NF6zU20zPDR{M{[xNy=>
U937-A/E-9/14/18  M1mzdGFxd3C2b4Ppd{BCe3OjeR?= NUnoXmVvOC5yMT:wMlEwOS9zMDFOwG0> MWS0PEBp NWTmRXRXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWHWXHdoOjR|MEC0OVY>
HT29 NH\YcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK3NkBp MXPJR|UxRTF2MEFCtVE4QSEQvF2= M{HpUVI1OTd{ME[x
SW48 M2HWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PNUFczKGh? NYnwOod{UUN3ME2xOU4zyrF4LkKg{txO Ml;QNlQyPzJyNkG=
HCT116 NH32NotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOyUIk4OiCq MmnHTWM2OD1zLkhCtVAvPCEQvF2= NGXHTnYzPDF5MkC2NS=>
HepG2 MoqxSpVv[3Srb36gRZN{[Xl? NEjwSpQxNjVxMTFOwG0> Mn3ONlQhcA>? MmDMSG1UVw>? NH\oTGd2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NUH3dFUxOjRzNE[4O|Q>
LS174T MVnGeY5kfGmxbjDBd5NigQ>? NI\BSJAxNjVxMTFOwG0> M1LKU|I1KGh? MXXEUXNQ NXPpXZJ{dGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> MmHLNlQyPDZ6N{S=
HepG2 MYTBdI9xfG:|aYOgRZN{[Xl? NEDDeWkyNzFyL{GwNEDPxE1? M4rib|ch\A>? M4W5T2ROW09? NYDMUpJxcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVOyOFE1Pjh5NB?=
LS174T M2f3d2Fxd3C2b4Ppd{BCe3OjeR?= M1q3dlEwOTBxMUCwJO69VQ>? NXnJcmRRPyCm MVjEUXNQ NWHUU|ZlcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFewd5kzPDF2Nki3OC=>
QBC-939 MmHhRZBweHSxc3nzJGF{e2G7 NEHmNmYyNzFyL{GwNEDPxE1? NYPMOYViPyCm NF;YW2dFVVOR NYiwSYtmcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NETj[VIzPDF2Nki3OC=>
U251 MmHNRZBweHSxc3nzJGF{e2G7 NXjrbIRXOS9zMD:xNFAh|ryP M4rKUlch\A>? MXrEUXNQ MV;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVSyOFE1Pjh5NB?=
HL-60 M3mxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\MNUDPxE1? Ml72OFghcA>? M{jkcolv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w MWSyOFAxODN{NB?=
MDA‑MB‑453 MX3GeY5kfGmxbjDBd5NigQ>? M4\FZVAvOi9zIN88US=> NIT2b2c4OiCq M4HENINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MVWyN|g1PDJ{OB?=
HCC1569 NIHwOlNHfW6ldHnvckBCe3OjeR?= MlrENE4zNzFizszN M{fqblczKGh? MYLjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M1j5S|I{QDR2MkK4
BT‑474 Mn\XSpVv[3Srb36gRZN{[Xl? M2jIbVAvOi9zIN88US=> MXy3NkBp MV\jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NWXFWodFOjN6NESyNlg>
AGS NHfzVYpCeG:ydH;zbZMhSXO|YYm= M3j0NlUwOTBxMkCvOVAh|ryP MUK0POKhcMLi MorHSG1UVw>? NVzZTotscW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? Mon3NlM2QDJ5OES=
A549 NV;5bo4{SXCxcITvd4l{KEG|c3H5 NHzOR3A2NzFyL{KwM|UxKM7:TR?= MYe0POKhcMLi NYDQR3VxTE2VTx?= MmXXbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MXmyN|U5Ojd6NB?=
AGS  M1vGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLSOU8yOC9{MD:1NEDPxE1? Moi2OFjDqGkEoB?= MXvEUXNQ NVu5UmJucW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh NILOTXIzOzV6Mke4OC=>
Kasumi-1 MWLBdI9xfG:|aYOgRZN{[Xl? Mnz1NE42KM7:TR?= M1jLUFQ5yqCqwrC= Mmrh[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MYmyN|Q6OzN2OB?=
OCI-AML3 NH\aeolCeG:ydH;zbZMhSXO|YYm= M1LQfFIvPSEQvF2= MmrVOFjDqGkEoB?= MoLn[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MY[yN|Q6OzN2OB?=
MV4-11 NX\UXHNlSXCxcITvd4l{KEG|c3H5 MojONk42KM7:TR?= NYXvPJZEPDkEoHlCpC=> MVfk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M2S5SVI{PDl|M{S4
NK  NGfCOoxEgXSxdH;4bZR6KEG|c3H5 NHO1UJkxNjB{LUKwJO69VQ>? Mon3OUBl MXXk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm M3PGPFI{OzJ6MEi4
NK  MUDBdI9xfG:|aYOgRZN{[Xl? M{e1cFAvODJvMkCg{txO NXHlbWg2PSCm MnHj[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MYSyN|MzQDB6OB?=
NK  M3rWSmZ2dmO2aX;uJGF{e2G7 M1rJe|AvODFvMkCg{txO MkjBOUBl MVnjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl MknPNlM{OjhyOEi=
MOLT4/DNR MVPGeY5kfGmxbjDBd5NigQ>? MV:1JO69VQ>? M2f6eVQh\A>? MoC3doVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> M1LBSVI{ODZyNUew
Jurkat/DOX NUi1fo5iTnWwY4Tpc44hSXO|YYm= MUK1JO69VQ>? M{fieVQh\A>? NXjVXGx6emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? M3m2bFI{ODZyNUew
MOLT4/DNR M3\PSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjnXY9OPSEQvF2= MX[0JIQ> NEfOPJFz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 M3SweVI{ODZyNUew
Jurkat/DOX M{XtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVe1JO69VQ>? MUK0JIQ> M2fEW5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= M{nrZlI{ODZyNUew
ccRCC  MUXBdI9xfG:|aYOgRZN{[Xl? MmTQNE4xOS1zMN88US=> M{DZdlczKGh? NH76VWZFVVOR NUXLWHY2cGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= M4fDbFIzQDJ4NE[3
TNBC  NFLRZohCeG:ydH;zbZMhSXO|YYm= MluxNE4xOS1zMN88US=> M2[4fVczKGh? NWX1UmZQTE2VTx?= MnP1bIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MnG2NlI5OjZ2Nke=
A498 M3zGeGFxd3C2b4Ppd{BCe3OjeR?= NYO3NWZKOC5yMT2xNO69VQ>? MkTEO|IhcA>? NVLLPFNETE2VTx?= NEHDN25qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NEHlNFMzOjh{NkS2Oy=>
KIJ265T NIjITnFCeG:ydH;zbZMhSXO|YYm= M4XMWVAvODFvMUFOwG0> NX;aVYp6PzJiaB?= NUG5UJpLTE2VTx?= MY\pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu M1XtblIzQDJ4NE[3
MDA-231 M1H2TmFxd3C2b4Ppd{BCe3OjeR?= NFjNO4gxNjBzLUGw{txO NU\GdIJlPzJiaB?= Mmi0SG1UVw>? M3K2fIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MUKyNlgzPjR4Nx?=
BT-20 MnLuRZBweHSxc3nzJGF{e2G7 NWflTI9qOC5yMT2xNO69VQ>? MmPoO|IhcA>? M33FUGROW09? MWXpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MWmyNlgzPjR4Nx?=
U937 NFPrb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnaW2VYPS1{MDFOwG0> MUOyOE81QC95MjDo MYrpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHfvZ5YzOjd4N{CyNS=>
HL60 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PsSFUuOjBizszN M1vwZ|I1NzR6L{eyJIg> MUDpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MXiyNlc3PzB{MR?=
U937 NEnYNY5CeG:ydH;zbZMhSXO|YYm= M2L6U|E2KM7:TR?= NHnLcYUzPC92OD:3NkBp NIDBfWZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M1y2ZVIzPzZ5MEKx
HL60 MYrBdI9xfG:|aYOgRZN{[Xl? Mm\1NVUh|ryP NUm5TpM1OjRxNEivO|IhcA>? MoTpbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1TPb|IzPzZ5MEKx
LS411N  MWXBdI9xfG:|aYOgRZN{[Xl? MnTMNE42KM7:TR?= MVe3NkBp M2DkZYlv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= NF7UXGQzOjR4MU[5OS=>
MDA-MB-231 NGqy[4FCeG:ydH;zbZMhSXO|YYm= Ml22NVAh|ryP NY[zZ|BsPDhiaB?= Mk\rdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUeyNVg5PzZ7Nx?=
MCF-7  M4fLdGFxd3C2b4Ppd{BCe3OjeR?= MnW5NVAh|ryP NWjYe2xSPDhiaB?= MkH4doVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{ThOVIyQDh5Nkm3
A375 NXTGSXp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HCRVAvPSEQvF2= MW[xM|UwQCCm MVTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MVuyNVc6PjZ{Mh?=
SKMEL1 NX60OYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvBNE42KM7:TR?= M1XMZVEwPS96IHS= M1nZOIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MW[yNVc6PjZ{Mh?=
SKMEL3 NVjUUVZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvDS5Z2OC53IN88US=> M3LyXVEwPS96IHS= M3TkUYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MoPvNlE4QTZ4MkK=
SKMEL28 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[wMlUh|ryP NXPCe3NiOS93L{ig[C=> NHq1[Y1qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NHfMV4YzOTd7Nk[yNi=>
MeWo NIW2ZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInSco4xNjVizszN NUjiZ5RVOS93L{ig[C=> NITrVIlqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NUfTOm1{OjF5OU[2NlI>
B16 NFj4S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITvUpYxNjVizszN MXexM|UwQCCm NW[1PG1VcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NI\Ob3czOTd7Nk[yNi=>
Ly 1 NX7OUHlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f5NFI1KGh? MoXFTWM2OD15LkOg{txO NX3odXRsOjF5N{KwOFk>
Ly 7 M3\N[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fjVVI1KGh? NIrvPY9KSzVyPUGwMlch|ryP NWLzb5lDOjF5N{KwOFk>
Su-DHL6 NYrVOXhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrzZlIzPCCq MUXJR|Ux97zgMkCg{txO M1fQNFIyPzd{MES5
Ly 10 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Xy[FI1KGh? M4Lib2lEPTExvK6yNEDPxE1? NEG3VJYzOTd5MkC0PS=>
RIVA MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPkNlQhcA>? M{nWcWlEPTExvK6yNEDPxE1? NXrWcY1FOjF5N{KwOFk>
Su-DHL2 M3nZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnpc5YzPCCq NX6xbXV5UUN3MP-8olIxKM7:TR?= NFrJTIEzOTd5MkC0PS=>
Ly 1 NXPNWWh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrJVWhyPDhiaB?= NE\TNGFKSzVyPUCuN|Qh|ryP M{TXcFIyPzd{MES5
Ly 7 NHHjcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPhOFghcA>? MYDJR|UxRTBwMEK1JO69VQ>? NV\WbW9NOjF5N{KwOFk>
Su-DHL6 M{Hj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXsU2lKPDhiaB?= NVzubnh[UUN3MP-8olIxKM7:TR?= MYCyNVc4OjB2OR?=
Ly 10 NYnIXFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3roNVQ5KGh? MYTJR|UxRTFwODFOwG0> MmTmNlE4PzJyNEm=
RIVA Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW3U|k3PDhiaB?= NWPxeXc6UUN3MP-8olIxKM7:TR?= M3fTVFIyPzd{MES5
Su-DHL2 NV3Vd5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILtdlY1QCCq NUTqe25{UUN3ME2xO{41KM7:TR?= MYSyNVc4OjB2OR?=
Ly 1 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\6dWRiPzJiaB?= NGq2WI5KSzVyPUCuNFEh|ryP MWCyNVc4OjB2OR?=
Ly 7 NYexT4YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXe3NkBp NFrpdGNKSzVyPUCuNFE5KM7:TR?= MVqyNVc4OjB2OR?=
Su-DHL6 NXr4UJgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTkeotkPzJiaB?= NFK0Z3VKSzVyPUGuOkDPxE1? M3\teFIyPzd{MES5
Ly 10 NI\J[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TqVlczKGh? MlHoTWM2OD1zLkKg{txO M1\BT|IyPzd{MES5
RIVA MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\aXXM6PzJiaB?= NVL2PWZEUUN3MP-8olIxKM7:TR?= NVPKW4NTOjF5N{KwOFk>
Su-DHL2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfsO|IhcA>? MnHXTWM2OD1zMT6yJO69VQ>? MonYNlE4PzJyNEm=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
in solvent
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

DNA Methyltransferase信号経路図

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID